EARLY BUILD · 15 license-and-service checked provider listings · No patient data collected
pPEPTIDE HEALTHDIRECTORY & EVIDENCE NOTES
← Compound library
Investigational / no FDA-approved-treatment claim

Cagrilintide + semaglutide (CagriSema)

A studied drug combination, not proof for a vendor-mixed blend.

Regulatory status and key limits

Investigational / no FDA-approved-treatment claim

A studied drug combination, not proof for a vendor-mixed blend.

Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.

Source checked October 10, 2026 · Editorial source review · Not medical advice
No dosing or purchase guidance. This information is not a recommendation to use a compound.

Purported uses, not established benefits

The combination is being investigated for weight reduction in adults with overweight or obesity.

REDEFINE 1 reports human trial findings in a defined population. This does not establish FDA approval or the quality, equivalence or safety of a separately sold blend.

Original research / claim context

A claimed use is not proof of safety, effectiveness or FDA approval. Research-purpose-only labeling does not authorize human use.

Evidence and source limits

The source linked here describes research or investigational use. It does not establish an FDA-approved indication for this compound or for a research-chemical product. A claimed use is not an established benefit.

Product identity, purity, route, safety and suitability remain separate questions. Research-purpose-only labeling does not authorize human use. This note provides no dosing, preparation or purchase guidance.

Original source

Original source: Cagrilintide + semaglutide (CagriSema) ↗

Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.